National Cancer Institute; Amended Notice of Meeting, 85896 [2023-27069]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
85896
Federal Register / Vol. 88, No. 236 / Monday, December 11, 2023 / Notices
stability and durability, potentially
reducing the frequency of booster shots.
• Platform for Future Vaccine
Development: The stabilization
techniques used in this technology
could be applied to other vaccine
formulations, paving the way for more
robust and effective vaccines against
various pathogens.
Competitive Advantages:
• Provides enhanced stability and
efficacy in norovirus VLP vaccines,
ensuring effectiveness even in
individuals with strong immune
responses who have previously shown
limited vaccine response.
• Its innovative design increases the
VLPs’ resistance to degradation, offering
a more durable and reliable option for
large-scale immunization programs.
Development Stage:
• Pre-Clinical.
Inventors: Lisa Lindesmith, Ralph
Baric, George Georgiou, Peter Kwong,
Raffaello Veradi, Yaroslav Tsybovsky,
Jason Gorman, Gwo-Yu Chuang and Li
Ou, all of NIAID.
Publications: Lu, Yuan et al.
‘‘Assessing sequence plasticity of a
virus-like nanoparticle by evolution
toward a versatile scaffold for vaccines
and drug delivery.’’ Proceedings of the
National Academy of Sciences of the
United States of America vol. 112,40
(2015): 12360–5. DOI: 10.1073/
pnas.1510533112 at https://doi.org/
10.1073/pnas.1510533112; Porta,
Claudine et al. ‘‘Rational engineering of
recombinant picornavirus capsids to
produce safe, protective vaccine
antigen.’’ PLoS pathogens vol. 9,3
(2013): e1003255. DOI: 10.1371/
journal.ppat.1003255 at https://doi.org/
10.1371/journal.ppat.1003255; Mateo,
Roberto et al. ‘‘Engineering viable footand-mouth disease viruses with
increased thermostability as a step in
the development of improved vaccines.’’
Journal of virology vol. 82,24 (2008):
12232–40. DOI: 10.1128/JVI.01553–08 at
https://doi.org/10.1128/jvi.01553-08;
Bertolotti-Ciarlet, Andrea et al.
‘‘Structural requirements for the
assembly of Norwalk virus-like
particles.’’ Journal of virology vol. 76,8
(2002): 4044–55. DOI: 10.1128/
jvi.76.8.4044–4055.2002 at https://
doi.org/10.1128/jvi.76.8.40444055.2002; Prasad, B V et al. ‘‘X-ray
crystallographic structure of the
Norwalk virus capsid.’’ Science (New
York, N.Y.) vol. 286,5438 (1999): 287–
90. DOI: 10.1126/science.286.5438.287
at https://doi.org/10.1126/
science.286.5438.287.
Intellectual Property: HHS Reference
No. E–178–2019–0; U.S. Provisional
Patent Application No. 63/091,824, filed
on October 14, 2020; PCT Patent
VerDate Sep<11>2014
17:35 Dec 08, 2023
Jkt 262001
Application No. PCT/US2021/55018,
filed October 14, 2021; U.S. National
Stage patent application, U.S. 18/
031,602, filed April 12, 2023.
Licensing Contact: To license this
technology, please contact Brian Bailey,
Ph.D.; 240–669–5128 or 301–201–9217;
bbailey@mail.nih.gov, and reference E–
178–2019.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Brian Bailey, Ph.D.; 240–669–
5128 or 301–201–9217; bbailey@
mail.nih.gov.
Dated: December 5, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–27112 Filed 12–8–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis, Panel SEP–
1: NCI Clinical and Translational Cancer
Research, February 7, 2024, 9:00 a.m. to
February 7, 2024, 5:00 p.m., National
Cancer Institute Shady Grove, 9609
Medical Center Drive, Room 7W108,
Rockville, Maryland, 20850 which was
published in the Federal Register on
November 17, 2023, FR Doc. 2023–
25490, 88 FR 80322.
This notice is being amended to
change the meeting date from February
7, 2024, to February 20, 2024. The
meeting location and time will stay the
same. The meeting is closed to the
public.
Dated: December 5, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–27069 Filed 12–8–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2023–0033; OMB No.
1660–NW171]
Agency Information Collection
Activities: Proposed Collection,
Comment Request; Generic Clearance
for FEMA’s Collection of Feedback on
Customer Satisfaction and Disaster
Recovery
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: 60-Day notice of new collection
and request for comments.
AGENCY:
The Federal Emergency
Management Agency (FEMA), as part of
its continuing effort to reduce
paperwork and respondent burden,
invites the general public to take this
opportunity to comment on a new
information collection. In accordance
with the requirements of the Paperwork
Reduction Act of 1995, this notice seeks
comments concerning a generic
clearance to collect feedback from
applicants on service delivery and their
subsequent disaster recovery.
DATES: Comments must be submitted on
or before February 9, 2024.
ADDRESSES: To avoid duplicate
submissions to the docket, please
submit comments at
www.regulations.gov under Docket ID
FEMA–2023–0033. Follow the
instructions for submitting comments.
All submissions received must
include the agency name and Docket ID.
Regardless of the method used to
submitting comments or material, all
submissions will be posted, without
change, to the Federal eRulemaking
Portal at https://www.regulations.gov,
and will include any personal
information you provide. Therefore,
submitting this information makes it
public. You may wisht to read the
Privacy and Security Notice that is
available via a link on the homepage of
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Kristin Brooks, Statistician, FEMA’s
Recovery Reporting and Analytics
Division, Customer Survey and Analysis
Section, at (202) 826–6291 or
Kristin.Brooks@fema.dhs.gov. You may
contact the Information Management
Division for copies of the proposed
collection of information at email
address: FEMA-Information-CollectionsManagement@fema.dhs.gov.
SUPPLEMENTARY INFORMATION: Executive
Order 12862, ‘‘Setting Customer Service
SUMMARY:
E:\FR\FM\11DEN1.SGM
11DEN1
]]>Agencies
[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Page 85896]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27069]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Institute Special Emphasis, Panel SEP-1: NCI Clinical and
Translational Cancer Research, February 7, 2024, 9:00 a.m. to February
7, 2024, 5:00 p.m., National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W108, Rockville, Maryland, 20850 which was
published in the Federal Register on November 17, 2023, FR Doc. 2023-
25490, 88 FR 80322.
This notice is being amended to change the meeting date from
February 7, 2024, to February 20, 2024. The meeting location and time
will stay the same. The meeting is closed to the public.
Dated: December 5, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-27069 Filed 12-8-23; 8:45 am]
BILLING CODE 4140-01-P
